{"id":"https://openalex.org/W3025199402","doi":"https://doi.org/10.1159/000507279","title":"Challenges of New Approaches in Metastatic Merkel Cell Carcinoma","display_name":"Challenges of New Approaches in Metastatic Merkel Cell Carcinoma","publication_year":2020,"publication_date":"2020-05-12","ids":{"openalex":"https://openalex.org/W3025199402","doi":"https://doi.org/10.1159/000507279","mag":"3025199402","pmid":"https://pubmed.ncbi.nlm.nih.gov/32518545","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7265742"},"language":"en","primary_location":{"id":"doi:10.1159/000507279","doi":"https://doi.org/10.1159/000507279","is_oa":true,"landing_page_url":"https://doi.org/10.1159/000507279","pdf_url":"https://www.karger.com/Article/Pdf/507279","source":{"id":"https://openalex.org/S62365728","display_name":"Case Reports in Oncology","issn_l":"1662-6575","issn":["1662-6575"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","norway-1","poland-40","russia-white-list-4","vabb-shw"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Case Reports in Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.karger.com/Article/Pdf/507279","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Ana Monteiro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]}],"countries":["PT"],"is_corresponding":true,"raw_author_name":"Ana Monteiro","raw_affiliation_strings":["Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014122899","display_name":"Emanuel Jose Gouveia","orcid":"https://orcid.org/0000-0001-5768-5539","observed_orcids":["https://orcid.org/0000-0001-5768-5539"]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Emanuel Gouveia","raw_affiliation_strings":["Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088392696","display_name":"Daniela Garcez","orcid":"https://orcid.org/0000-0002-0684-7347","observed_orcids":["https://orcid.org/0000-0002-0684-7347"]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Daniela Garcez","raw_affiliation_strings":["Neurology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil E.P.E, Lisbon, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil E.P.E, Lisbon, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033172105","display_name":"Sara Donato","orcid":"https://orcid.org/0000-0001-8704-5292","observed_orcids":["https://orcid.org/0000-0001-8704-5292"]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Sara Donato","raw_affiliation_strings":["Endocrinology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal"],"raw_orcid":"https://orcid.org/0000-0001-8704-5292","affiliations":[{"raw_affiliation_string":"Endocrinology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002113898","display_name":"Diogo Alexandre Martins-Branco","orcid":"https://orcid.org/0000-0002-7214-4818","observed_orcids":["https://orcid.org/0000-0002-7214-4818"]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Diogo Martins-Branco","raw_affiliation_strings":["Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Joana Marques","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Joana Marques","raw_affiliation_strings":["Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082018913","display_name":"Hugo Nunes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Hugo Nunes","raw_affiliation_strings":["Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075354066","display_name":"Maria Jos\u00e9 Passos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Maria Jos\u00e9 Passos","raw_affiliation_strings":["Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109389618","display_name":"Ana Isabel Clara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Ana Isabel Clara","raw_affiliation_strings":["Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5104059155","display_name":"Ant\u00f3nio Moreira","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Ant\u00f3nio Moreira","raw_affiliation_strings":["Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, E.P.E, Lisbon, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210103180"],"apc_list":{"value":1170,"currency":"USD","value_usd":1170},"apc_paid":{"value":1170,"currency":"USD","value_usd":1170},"fwci":0.6935,"has_fulltext":true,"cited_by_count":10,"citation_normalized_percentile":{"value":0.68878932,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"13","issue":"2","first_page":"501","last_page":"507"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.006800000090152025,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11306","display_name":"Nonmelanoma Skin Cancer Studies","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-merkel-cell-carcinoma","display_name":"metastatic Merkel cell carcinoma","score":0.8970000147819519},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9710000157356262},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.8870000243186951},{"id":"https://openalex.org/keywords/diabetic-ketoacidosis","display_name":"diabetic ketoacidosis","score":0.9929999709129333},{"id":"https://openalex.org/keywords/paraneoplastic-syndrome","display_name":"paraneoplastic syndrome","score":0.9610000252723694},{"id":"https://openalex.org/keywords/onconeuronal-antibodies","display_name":"onconeuronal antibodies","score":0.7620000243186951},{"id":"https://openalex.org/keywords/immunotherapy-toxicity","display_name":"immunotherapy toxicity","score":0.6800000071525574},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8370000123977661}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9156464338302612},{"id":"https://openalex.org/C2778342957","wikidata":"https://www.wikidata.org/wiki/Q1711744","display_name":"Merkel cell carcinoma","level":3,"score":0.7539342045783997},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.7206571102142334},{"id":"https://openalex.org/C2780291066","wikidata":"https://www.wikidata.org/wiki/Q1570264","display_name":"Merkel cell","level":4,"score":0.6727311611175537},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.6364576816558838},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5853613615036011},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.5113827586174011},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.45895251631736755},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4296317398548126},{"id":"https://openalex.org/C2777546739","wikidata":"https://www.wikidata.org/wiki/Q33525","display_name":"Carcinoma","level":2,"score":0.26177778840065},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2476501762866974}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.1159/000507279","doi":"https://doi.org/10.1159/000507279","is_oa":true,"landing_page_url":"https://doi.org/10.1159/000507279","pdf_url":"https://www.karger.com/Article/Pdf/507279","source":{"id":"https://openalex.org/S62365728","display_name":"Case Reports in Oncology","issn_l":"1662-6575","issn":["1662-6575"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","norway-1","poland-40","russia-white-list-4","vabb-shw"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Case Reports in Oncology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7265742","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7265742","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Case Rep Oncol","raw_type":"Text"},{"id":"pmid:32518545","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32518545","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Case reports in oncology","raw_type":"Case Reports"},{"id":"pmh:oai:doaj.org/article:0a0c8a0a52e2460eb34b2f212c3c0408","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/0a0c8a0a52e2460eb34b2f212c3c0408","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Case Reports in Oncology, Vol 13, Iss 2, Pp 501-507 (2020)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1159/000507279","doi":"https://doi.org/10.1159/000507279","is_oa":true,"landing_page_url":"https://doi.org/10.1159/000507279","pdf_url":"https://www.karger.com/Article/Pdf/507279","source":{"id":"https://openalex.org/S62365728","display_name":"Case Reports in Oncology","issn_l":"1662-6575","issn":["1662-6575"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","norway-1","poland-40","russia-white-list-4","vabb-shw"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Case Reports in Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Case Report","id":"https://openalex.org/study-designs/case-report"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3025199402.pdf","grobid_xml":"https://content.openalex.org/works/W3025199402.grobid-xml"},"referenced_works_count":10,"referenced_works":["https://openalex.org/W1909452331","https://openalex.org/W2198093519","https://openalex.org/W2339890238","https://openalex.org/W2554828182","https://openalex.org/W2789991785","https://openalex.org/W2791905160","https://openalex.org/W2806531478","https://openalex.org/W2808507967","https://openalex.org/W2897176491","https://openalex.org/W2899878755"],"related_works":["https://openalex.org/W3090924625","https://openalex.org/W4413275175","https://openalex.org/W3081472817","https://openalex.org/W4206725320","https://openalex.org/W7131281562","https://openalex.org/W2897176491","https://openalex.org/W3087236879","https://openalex.org/W2947960513","https://openalex.org/W4405930179","https://openalex.org/W4385331932"],"abstract_inverted_index":{"Merkel":[0,59],"cell":[1,60],"carcinoma":[2,61],"is":[3,17,36,147,162],"a":[4,18,50,69,92,104,112,116,155],"rare":[5],"and":[6,10,27,43,94,137],"aggressive":[7],"cutaneous":[8],"tumor,":[9],"the":[11,31,81,89,98,133,143,151,165],"use":[12,33],"of":[13,34,41,52,158],"checkpoint":[14],"inhibitors":[15],"immunotherapy":[16,35,127],"recent":[19],"indication":[20],"in":[21,168,172],"its":[22],"metastatic":[23,58],"setting,":[24],"both":[25],"first":[26],"second":[28],"line.":[29],"However,":[30],"widespread":[32],"associated":[37,125],"with":[38,57,63,85,115,126,154],"an":[39,53,122],"increase":[40],"acute":[42],"late":[44],"immune-mediated":[45,71],"adverse":[46,72],"events.":[47],"We":[48],"present":[49],"case":[51],"elderly":[54],"fit":[55],"patient":[56,90],"treated":[62],"pembrolizumab":[64],"who":[65],"developed":[66],"diabetic":[67],"ketoacidosis,":[68],"severe":[70],"event.":[73,83],"A":[74],"multidisciplinary":[75],"approach":[76],"was":[77,135],"crucial":[78],"to":[79,97,111,139,149],"overcome":[80],"life-threatening":[82],"Even":[84],"early":[86],"treatment":[87,99],"stop,":[88],"had":[91],"significant":[93],"durable":[95],"response":[96],"for":[100],"15":[101,159],"months.":[102],"Meanwhile,":[103],"progressive":[105],"pan-cerebellar":[106],"syndrome":[107,114],"emerged,":[108],"possible":[109],"due":[110],"paraneoplastic":[113],"negative":[117],"onco-neuronal":[118],"antibody":[119],"panel,":[120],"although":[121],"autoimmune":[123],"etiology":[124],"could":[128],"not":[129],"be":[130],"excluded.":[131],"Unfortunately,":[132],"situation":[134],"irreversible":[136],"refractory":[138],"immunomodulatory":[140],"treatment.":[141],"Despite":[142],"unpredictable":[144],"toxicity,":[145],"it":[146],"important":[148],"note":[150],"efficacy":[152],"profile,":[153],"progression-free":[156],"survival":[157],"months,":[160],"which":[161],"higher":[163],"than":[164],"one":[166],"reported":[167],"reference":[169],"clinical":[170],"trials":[171],"this":[173],"setting.":[174]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2020-05-21T00:00:00"}